Skip to main content
Fig. 1 | Trials

Fig. 1

From: Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Fig. 1

Study design. The asterisk indicates that patients with moderate renal dysfunction (estimated glomerular filtration rate 30–60 mL/min/1.73 m2) will be allowed to be administered filgotinib 100 mg/day

Back to article page

Trials

ISSN: 1745-6215